Clinical trials are underway in the US to achieve localized gene delivery for diseased joints in order to achieve sustained drug production with regards to osteoarthritis or rheumatoid arthritis.
Reports suggest the first arthritis gene therapy was recently approved in Korea. In the article, a detailed overview of current trends in the field, along with gene delivery strategies and the current clinical trials and product development is available.
‘Gene Delivery to Joints by Intra-Articular Injection’ is an article which provides useful insights in the field. It is coauthored by Steven Ghivizzani, University of Florida College of Medicine (Gainesville, FL), Christopher Evans of Mayo Clinic (Rochester, MN), and Paul Robbins of The Scripps Research Institute (Jupiter, FL).
In the article, the author especially draws attention to the various advantages of gene therapy for localized drug delivery for the joints which includes the intake of higher drug concentrations for the disease, in addition to the exposure of nontarget organs.
Furthermore, the article also elaborates the selection of therapeutic transgene and an optimal delivery vector and reviews human clinical trials used in arthritis gene therapy in the US that have either taken place or are yet pending.
“Arthritis is the most common disorder that is likely to be treatable with gene therapy within the next several years,” commented Editor-in-Chief Terence R. Flotte, MD. “This latest installment of our Target Organ series provides a comprehensive review of the optimal platforms for treating these potentially disabling disorders,” he adds.